 | • レポートコード：B-MOR-040816 • 出版社/出版日：Mordor Intelligence / 2018年2月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・バイオ |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、血糖測定用試験紙の世界市場について調べ、血糖測定用試験紙の世界規模、市場動向、市場環境、デバイスタイプ別（血糖測定器、血糖測定用試験紙、ランセット、連続的グルコース監視装置（CGM）、その他）分析、用途別（診断センター・診療所、病院、在宅医療）分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・血糖測定用試験紙の世界市場インサイト ・血糖測定用試験紙の世界市場環境 ・血糖測定用試験紙の世界市場動向 ・血糖測定用試験紙の世界市場規模 ・血糖測定用試験紙の世界市場規模：デバイスタイプ別（血糖測定器、血糖測定用試験紙、ランセット、連続的グルコース監視装置（CGM）、その他） ・血糖測定用試験紙の世界市場規模：用途別（診断センター・診療所、病院、在宅医療） ・血糖測定用試験紙の世界市場：地域別市場規模・分析 ・血糖測定用試験紙の北米市場規模・予測 ・血糖測定用試験紙のアメリカ市場規模・予測 ・血糖測定用試験紙のヨーロッパ市場規模・予測 ・血糖測定用試験紙のアジア市場規模・予測 ・血糖測定用試験紙の日本市場規模・予測 ・血糖測定用試験紙の中国市場規模・予測 ・血糖測定用試験紙のインド市場規模・予測 ・血糖測定用試験紙の韓国市場規模・予測 ・関連企業情報・競争状況 |
In 2017, the global blood glucose test strips market was estimated at around USD 11,000 million. The market is expected to register a CAGR of about 6.5% during 2018-2023 (the forecast period). North America, followed by Asia-Pacific, accounts for the largest share in the blood glucose test strips market.
Convenience of CGM over Conventional Monitoring
Continuous glucose monitoring (CGM) provides a frequent and real-time feedback about glucose levels and retrospective 24-hrs glucose profiles. Incorporating CGM in the treatment of type 1 diabetes (T1D) has given potential advantages over conventional self-monitoring of blood glucose (SMBG). The real-time use of CGM results can equip people with T1D and parents of youths with T1D, to respond promptly and address glycemic excursions, minimizing, both, hyperglycemia and hypoglycemia. Retrospective use of CGM profiles can reveal recurring glycemic fluctuations that are not apparent with conventional SMBG, permitting regimen adjustments to stabilize glucose control. As CGM systems have become more widespread, the market for blood glucose test strip is likely to experience growth. Moreover, owing to the rising diabetic population and technological advancements, this market is expected to grow and combat diabetes.
High Cost Per Strip
Diabetes treatment requires constant monitoring of glucose levels. If blood glucose levels are not monitored regularly, it can lead to severe complications. Diabetes management process is an expensive service. At large scale, patients use blood glucose test strips. The retail cost of these strips varies from 50 cents per strip to as high as USD 5 per strip. Since, constant monitoring is necessary for diabetic patients, the cost often becomes a problem. Although various countries, like the United Kingdom, provide reimbursements for prescribed test strips, the majority patients have to pay for them from their pockets. The frequency of monitoring glucose levels depends on the type of diabetes and varies from patient to patient. For type 1 diabetes patients, at least four tests are advised per day. If the patient is using insulin injections, the count can go up to seven tests per day. Therefore, if a patient performs 5-6 tests in a day, the average expenditure on test strips would be over USD 180 each month. These expenses add to the already high diabetes management costs and are impeding the market growth.
North America to Dominate the Market Growth
North America accounted for the largest share of 56% of the global market, owing to the availability of healthcare reimbursements and the fastest adoption rate for new medical technologies. Europe is also the leading region in the global blood glucose test strips market. Asia-Pacific is the fastest growing region for blood glucose test strips market and portrays a huge potential for growth in the future, due to the increasing government initiatives to combat diabetes and corporate investments to streamline R&D in diabetes.
Key Developments in the Market
• January 2018: Ascensia Diabetes Care announced the expansion of its strategic alliance with Insulet Corporation, a leader in tubeless insulin pump technology, by signing a global commercial agreement. This expansion follows the worldwide non-exclusive development agreement that Ascensia announced in June 2017, to connect its CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) with Insulet’s next-generation Omnipod System (Omnipod DASH™).
Major Players: ROCHE DIAGNOSTICS, LIFESCAN, BAYER HEALTHCARE, ABBOTT LABORATORIES, ARKRAY INC., ACON LABORATORIES, APEX BIOTECHNOLOGY CORPORATION, ASCENSIA DIABETES CARE, HMD BIOMEDICAL, B. BRAUN MELSUNGEN AG amongst others.
Reasons to Purchase this Report
• Current and future the blood glucose test strips market outlook in the developed and emerging markets
• Analyzing various market perspectives, with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• The regions that are expected to witness fastest growth during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Convenience of CGM Over Conventional Monitoring
6.1.2 Early Detection of Hypo and Hyperglycemic Diabetes
6.1.3 Technological Innovations
6.1.4 Global Rise in Diabetic Population
6.2 Market Restraints
6.2.1 Developed Markets Have Reached Saturation
6.2.2 High Cost per Strip
6.2.3 Difficulty in Product Differentiation
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Device Type
7.1.1 Blood Glucose Meter
7.1.2 Blood Glucose Testing Strips
7.1.3 Lancets
7.1.4 Continuous Glucose Monitoring Devices (CGM)
7.1.5 Others
7.2 By Application
7.2.1 Diagnostic Centers/Clinics
7.2.2 Hospitals
7.2.3 Home Setting
7.3 By Geography
7.3.1 North America
7.3.1.1 US
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 Germany
7.3.2.2 UK
7.3.2.3 France
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe (RoE)
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of the Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Lifescan
9.2 Bayer Healthcare Ag
9.3 Abbott Laboratories
9.4 Arkay Inc.
9.5 Roche Diagnostic
9.6 Acon Laboratories
9.7 Apex Biotechnology Corporation
9.8 Ascensia Diabetes Care Holdings
9.9 HMD Biomedical
9.10 B. Braun Melsungen AG
9.11 Others
10. Future of the Market